Rituximab for the first-line treatment of chronic lymphocytic leukaemia | Guidance and guidelines

Documents

A list of downloadable documents created during development.

Background information

Leukaemia (chronic lymphocytic, first line) - rituximab: review decision - March 2014 information
Appendix B: GE decision paper - March 2014 08 April 2014 110.09 KB
Leukaemia (chronic lymphocytic, first line) - rituximab: Review Proposal - January 2014 information
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix A - provisional matrix of stakeholders 20 January 2014 100.52 KB
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive 20 January 2014 446.11 KB
Leukaemia (chronic lymphocytic, first line) - rituximab: review update - October 2012 information
Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - December 2010 information
NICE issues final guidance on the use of rituximab for first line chronic lymphocytic leukaemia 06 December 2013 36.72 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination information
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination 15 June 2009 137.94 KB
Response to consultee, commentator and public comments on the ACD and comments from website consultation 15 June 2009 120.08 KB
Consultee and commentator comments on the ACD
Chronic Lymphocytic Leukaemia Support Association 15 June 2009 19.99 KB
Department of Health 15 June 2009 12.85 KB
Leukaemia CARE 15 June 2009 13.28 KB
Roche 15 June 2009 99.73 KB
Royal College of Nursing 15 June 2009 18.71 KB
Royal College of Pathologists 15 June 2009 8.32 KB
Comments from website consultation 15 June 2009 20.11 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation
Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation document information
Leukaemia (chronic lymphocytic, first line) - rituximab: evaluation report
Pre-meeting briefing 26 March 2009 114.83 KB
Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report 26 March 2009 3.61 MB
Non-manufacturer submissions
Chronic Lymphocytic Leukaemia Support 26 March 2009 49.31 KB
Hampshire PCT 26 March 2009 24.26 KB
Royal College of Nursing 26 March 2009 26.65 KB
Royal College of Physicians, Medical Oncology Joint Special Committee (on behalf of the NCRI/RCP/RCR/ACP/JCCO) 26 March 2009 89.35 KB
UK CLL Forum 26 March 2009 27.16 KB
UK CLL Forum, Royal College of Pathologists & British Society for Haematology 26 March 2009 40.5 KB
Expert written personal statements
Barnard 26 March 2009 97.11 KB
Milligan 26 March 2009 14.03 KB
Pettitt 26 March 2009 19.32 KB
Williams Durkin 26 March 2009 41.49 KB
Manufacturer submission
Roche submission 26 March 2009 4.22 MB
Manufacturer response to clarification letter 26 March 2009 308.73 KB
Manufacturer response to supplementary clarification letter 26 March 2009 18.33 KB
NICE clarification letter 26 March 2009 35.33 KB
NICE supplementary clarification letter 26 March 2009 16.08 KB
Utility Measurement Study for Patients with Chronic Lymphocytic Leukaemia: Interim Report 26 March 2009 165.38 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (updated following CHMP positive opinion)

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope 24 September 2008 27.49 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope 24 September 2008 27.49 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators 24 September 2008 47.26 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope 24 September 2008 73.56 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix 24 September 2008 23.31 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope 24 September 2008 30.59 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators 24 September 2008 47.8 KB

Background information

Appendix B: GE decision paper - March 2014 08 April 2014 110.09 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix A - provisional matrix of stakeholders 20 January 2014 100.52 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive 20 January 2014 446.11 KB

NICE issues final guidance on the use of rituximab for first line chronic lymphocytic leukaemia 06 December 2013 36.72 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination 15 June 2009 137.94 KB

Response to consultee, commentator and public comments on the ACD and comments from website consultation 15 June 2009 120.08 KB

Consultee and commentator comments on the ACD

Chronic Lymphocytic Leukaemia Support Association 15 June 2009 19.99 KB

Department of Health 15 June 2009 12.85 KB

Leukaemia CARE 15 June 2009 13.28 KB

Roche 15 June 2009 99.73 KB

Royal College of Nursing 15 June 2009 18.71 KB

Royal College of Pathologists 15 June 2009 8.32 KB

Comments from website consultation 15 June 2009 20.11 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation

Leukaemia (chronic lymphocytic, first line) - rituximab: evaluation report

Pre-meeting briefing 26 March 2009 114.83 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report 26 March 2009 3.61 MB

Non-manufacturer submissions

Chronic Lymphocytic Leukaemia Support 26 March 2009 49.31 KB

Hampshire PCT 26 March 2009 24.26 KB

Royal College of Nursing 26 March 2009 26.65 KB

Royal College of Physicians, Medical Oncology Joint Special Committee (on behalf of the NCRI/RCP/RCR/ACP/JCCO) 26 March 2009 89.35 KB

UK CLL Forum 26 March 2009 27.16 KB

UK CLL Forum, Royal College of Pathologists & British Society for Haematology 26 March 2009 40.5 KB

Expert written personal statements

Barnard 26 March 2009 97.11 KB

Milligan 26 March 2009 14.03 KB

Pettitt 26 March 2009 19.32 KB

Williams Durkin 26 March 2009 41.49 KB

Manufacturer submission

Roche submission 26 March 2009 4.22 MB

Manufacturer response to clarification letter 26 March 2009 308.73 KB

Manufacturer response to supplementary clarification letter 26 March 2009 18.33 KB

NICE clarification letter 26 March 2009 35.33 KB

NICE supplementary clarification letter 26 March 2009 16.08 KB

Utility Measurement Study for Patients with Chronic Lymphocytic Leukaemia: Interim Report 26 March 2009 165.38 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (updated following CHMP positive opinion)

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope 24 September 2008 27.49 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope 24 September 2008 27.49 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators 24 September 2008 47.26 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope 24 September 2008 73.56 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix 24 September 2008 23.31 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope 24 September 2008 30.59 KB

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators 24 September 2008 47.8 KB